This Oncology eBook brings together a collection of insights that reflect the rapid pace of innovation in cancer research, diagnosis, and treatment. As precision medicine continues to transform oncology, advances in imaging, artificial intelligence (AI), molecular profiling, and targeted therapies are providing new opportunities to improve patient outcomes across a broad range of cancers.
Designed for researchers, clinicians, and oncology professionals, this edition explores the technologies and scientific discoveries that are reshaping how cancers are detected, characterized, and treated, while offering deeper insight into the biological mechanisms that influence disease progression and therapeutic response.
We begin with 'The impact of PD-1-positive immune cell ratios and TLS on gastric cancer treatment response', which examines how features of the tumor immune microenvironment may help predict responses to immunotherapy. This is followed by 'Radiology AI systems flag breast cancer signs six years before diagnosis', highlighting the growing role of AI in enabling earlier cancer detection.
'How advanced imaging is helping decode breast cancer resistance' demonstrates how imaging technologies are improving our understanding of treatment resistance.
The collection continues with 'Fewer radiotherapy sessions for prostate cancer show minimal side effects', which examines efforts to optimize treatment while reducing patient burden. 'Gene test helps many breast cancer patients avoid chemotherapy' highlights how genomic testing is supporting more personalized treatment decisions, while 'Uncovering systemic dysfunction in colorectal cancer with multiomics' showcases the value of integrating multiple biological datasets to better understand disease mechanisms.
Finally, 'AI-supported mammography improves early detection of breast cancer' reinforces the growing impact of AI in cancer screening, and 'Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma' concludes the collection by highlighting an emerging therapeutic approach for one of the most challenging forms of brain cancer.
Overall, this eBook demonstrates how advances in precision diagnostics, molecular biology, AI, and therapeutic innovation are driving the future of oncology and supporting more personalized approaches to cancer care.
About TissueGnostics
TissueGnostics (TG) is an Austrian company focusing on integrated solutions for high-content and/or high-throughput scanning and analysis of biomedical, veterinary, natural sciences, and technical microscopy samples.
TG was founded by scientists from the Vienna University Hospital (AKH) in 2003. It is now a globally active company with subsidiaries in the EU, the USA, and China, and customers in 30 countries.
TissueGnostics portfolio
TG scanning systems are currently based on versatile automated microscopy systems with or without image analysis capabilities. The company strives to provide cutting-edge technology solutions, such as multispectral imaging and context-based image analysis, as well as established features like Z-Stacking and Extended Focus. This is combined with a strong emphasis on automation, ease of use of all solutions, and the production of publication-ready data.
The TG systems offer integrated workflows, i.e., scan and analysis, for digital slides or images of tissue sections, Tissue Microarrays (TMA), cell culture monolayers, smears, and other samples on slides and oversized slides, in Microtiter plates, Petri dishes, and specialized sample containers. TG also provides dedicated workflows for FISH, CISH, and other dot structures.
TG analysis software, in addition to being integrated into full systems, is fully standalone and supports a wide variety of scanner image formats, as well as digital images from any microscope.
TG cooperations
TG continuously collaborates with research groups and other companies in the industry to develop novel tools and applications for its customers.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.